Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Overview

NASDAQ:TBPH - KYG8807B1068 - Common Stock

14.05 USD
+0.32 (+2.29%)
Last: 9/4/2025, 8:00:01 PM
14.05 USD
0 (0%)
After Hours: 9/4/2025, 8:00:01 PM

TBPH Key Statistics, Chart & Performance

Key Statistics
52 Week High14.55
52 Week Low7.88
Market Cap707.56M
Shares50.36M
Float48.06M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.38
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO05-16 2014-05-16
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


TBPH short term performance overview.The bars show the price performance of TBPH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

TBPH long term performance overview.The bars show the price performance of TBPH in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of TBPH is 14.05 USD. In the past month the price increased by 25.67%. In the past year, price increased by 75.41%.

THERAVANCE BIOPHARMA INC / TBPH Daily stock chart

TBPH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 46 703.13B
JNJ JOHNSON & JOHNSON 17.88 430.51B
AZN ASTRAZENECA PLC-SPONS ADR 18.42 253.56B
NVO NOVO-NORDISK A/S-SPONS ADR 14.39 249.45B
NVS NOVARTIS AG-SPONSORED ADR 14.51 248.60B
MRK MERCK & CO. INC. 10.92 209.94B
PFE PFIZER INC 7.24 139.52B
SNY SANOFI-ADR 10.26 110.56B
BMY BRISTOL-MYERS SQUIBB CO 6.94 95.03B
GSK GSK PLC-SPON ADR 8.8 79.80B
ZTS ZOETIS INC 24.63 67.90B
TAK TAKEDA PHARMACEUTIC-SP ADR 52.72 48.29B

About TBPH

Company Profile

TBPH logo image Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

Company Info

THERAVANCE BIOPHARMA INC

Ugland House, South Church Street

GEORGE TOWN GRAND CAYMAN KY1-1104 KY

CEO: Rick E Winningham

Employees: 97

TBPH Company Website

TBPH Investor Relations

Phone: 16508086000

THERAVANCE BIOPHARMA INC / TBPH FAQ

What is the stock price of THERAVANCE BIOPHARMA INC today?

The current stock price of TBPH is 14.05 USD. The price increased by 2.29% in the last trading session.


What is the ticker symbol for THERAVANCE BIOPHARMA INC stock?

The exchange symbol of THERAVANCE BIOPHARMA INC is TBPH and it is listed on the Nasdaq exchange.


On which exchange is TBPH stock listed?

TBPH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for THERAVANCE BIOPHARMA INC stock?

11 analysts have analysed TBPH and the average price target is 18.77 USD. This implies a price increase of 33.58% is expected in the next year compared to the current price of 14.05. Check the THERAVANCE BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is THERAVANCE BIOPHARMA INC worth?

THERAVANCE BIOPHARMA INC (TBPH) has a market capitalization of 707.56M USD. This makes TBPH a Small Cap stock.


How many employees does THERAVANCE BIOPHARMA INC have?

THERAVANCE BIOPHARMA INC (TBPH) currently has 97 employees.


What are the support and resistance levels for THERAVANCE BIOPHARMA INC (TBPH) stock?

THERAVANCE BIOPHARMA INC (TBPH) has a support level at 13.87 and a resistance level at 14.06. Check the full technical report for a detailed analysis of TBPH support and resistance levels.


Is THERAVANCE BIOPHARMA INC (TBPH) expected to grow?

The Revenue of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 79.49% in the next year. Check the estimates tab for more information on the TBPH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy THERAVANCE BIOPHARMA INC (TBPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does THERAVANCE BIOPHARMA INC (TBPH) stock pay dividends?

TBPH does not pay a dividend.


When does THERAVANCE BIOPHARMA INC (TBPH) report earnings?

THERAVANCE BIOPHARMA INC (TBPH) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of THERAVANCE BIOPHARMA INC (TBPH)?

THERAVANCE BIOPHARMA INC (TBPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).


What is the Short Interest ratio of THERAVANCE BIOPHARMA INC (TBPH) stock?

The outstanding short interest for THERAVANCE BIOPHARMA INC (TBPH) is 7.4% of its float. Check the ownership tab for more information on the TBPH short interest.


TBPH Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to TBPH. When comparing the yearly performance of all stocks, TBPH is one of the better performing stocks in the market, outperforming 91.43% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TBPH Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to TBPH. The financial health of TBPH is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TBPH Financial Highlights

Over the last trailing twelve months TBPH reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS decreased by -60.47% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.88%
ROA 3.06%
ROE 5.8%
Debt/Equity 0.14
Chartmill High Growth Momentum
EPS Q2Q%-92.86%
Sales Q2Q%83.75%
EPS 1Y (TTM)-60.47%
Revenue 1Y (TTM)24.48%

TBPH Forecast & Estimates

11 analysts have analysed TBPH and the average price target is 18.77 USD. This implies a price increase of 33.58% is expected in the next year compared to the current price of 14.05.

For the next year, analysts expect an EPS growth of 186.4% and a revenue growth 79.49% for TBPH


Analysts
Analysts80
Price Target18.77 (33.59%)
EPS Next Y186.4%
Revenue Next Year79.49%

TBPH Ownership

Ownership
Inst Owners91.75%
Ins Owners4.71%
Short Float %7.4%
Short Ratio11.14